Patient No.
Vaccine brand
Route
Disease category
Age
Sex
Diagnosis
Mutation
COVID-19 breakthrough
Current medications
ALC 109/L IgG mg/dl
1 BB MM Dysregulation 19 M HIDS AR MVK:c.928G>A,p.V310M 1 mo after dose 3 Anakinra, MTX 3.14 NA
2 BB MM Humoral 29 M XLA XL BTK:c.1567-2A>T (splicing) 3 mo before dose 3 SCIG 1.55 1075
3 BB MM Humoral 28 M XLA XL BTK:c.942A>G (splicing) / SCIG 1.25 1241
4 BB MM Innate 28 M STAT1 GOF AD STAT1:c.800C>T,p.A267V / / NA NA
5 BB MM Phagocytic 16 M X-CGD, post-HSCT XL CYBB:c.1437C>A ,p.Y479* / / NA NA
6 BBB MMD Combined 16 F STAT3 LOF AD STAT3:c.2134T>C,p.C712R / IVIG 1.99 NA
7 BBB MMD Dysregulation 26 M XMEN XL MAGT1:c.916delC,p.L306fs / IVIG 1.43 939
8 BBB MMD Humoral 13 M XLA XL BTK:c.1696C>T,p.P566S / IVIG 5.55 1020
9 BBB MMD Innate 15 M STAT1 GOF AD STAT1:c.1170G>A,p.M390I / / NA NA
10 BBB MMM Combined 21 M AT / / IVIG 0.92 824
11 BBB MMM Combined 49 M XLT XL WAS:c.134C>T,p.T45M / / 1.2 NA
12 BBB MMM Dysregulation 18 F HLH / / IVIG, MMF, pred 0.52 803
13 BBB MMM Humoral 34 M XLA XL BTK:c.887del,p.K296Sfs*35 1 wk after dose 3 IVIG 1.01 1089
14 BBB MMM Humoral 13 M XLA XL BTK:c.1111T>C,p.S371P / IVIG 1.8 750
15 BBB MMM Humoral 30 M XLA XL BTK:c.41C>A,p.S14Y / IVIG 1.7 1044
16 BBB MMM Innate 30 M STAT1 GOF AD STAT1:c.1151G>A,p.G384D / / 0.99 1148
17 BBB MMM Innate 19 F STAT1 GOF AD STAT1:c.1074G>T,p.L358F / / 0.45 1111
18 BBB MMM Phagocytic 50 F X-CGD carrier XL CYBB:c.469C>T,p.R157* / / 1.59 NA
19 BBB MMM Phagocytic 23 M X-CGD, post-HSCT XL CYBB:c.1498G>C ,p.D500H / / 2.66 1077
20 BBB MMM Phagocytic 14 M X-CGD XL CYBB:c.469C>T,p.R157* / / 2.17 NA
21 CC MM Combined 13 M XLT XL WAS:c.116T>G,p.L39R / / NA NA
22 CC MM Humoral 5 F Agamma / 2 wk after dose 1 IVIG 1.32 1119
23 CC MM Humoral 11 M XLA XL BTK:c.3G>T,p.M1I / IVIG 2.58 814
24 CC MM Humoral 30 M XLA XL BTK:c.3G>T,p.M1I / IVIG 2.14 1409
25 CC MM Phagocytic 10 F AR-CGD, post-HSCT AR CYBA:c.371C>T,p.A124V / / 2.05 973
26 CCC DDD Combined 15 M X-SCID, post-HSCT XL IL2RG:c.562C>T,p.Q188* 1 mo before dose 3 / 2.23 1289
27 CCC DDD Innate 8 M CARD9 AR het CARD9:c.586A>G,p.K196E and c.1526G>A,p.R509K / / 1.91 NA
28 CCC MMM Dysregulation 8 M CINCA AD NLRP3:c.1711G>C,p.G571R / Canakinumab NA NA
29 CCC MMM Dysregulation 15 M CINCA AD somatic mosaicism NLRP3:c. 998G>T,p.S333I 1 mo after dose 3 MTX, canakinumab 1.6 1361
30 CCC MMM Humoral 5 M XLA XL BTK:c.1559G>C,p.R520P / IVIG 2.7 717
31 CCC MMM Humoral 7 M XLA XL BTK:c.1559G>C,p.R520P / IVIG 2 613
32 CCC MMM Humoral 19 F CVID / / IVIG, HCQ, MMF, pred 2.14 864
33 CCC MMM Humoral 18 M XLA XL BTK:c.332T>C,p.L111P / IVIG 1.7 NA
34 CCC MMM Humoral 32 M XLA XL BTK:c.41C>A,p.S14Y / IVIG 1.8 1076
35 CCC MMM Humoral 14 M XLA XL BTK:c.947_948del,p.T316Sfs*6 / IVIG 3.04 1279
36 CCC MMM Humoral 15 M XLA XL BTK:c.1535T>C,p.L512P 3 mo after dose 3 IVIG 2.12 916
37 CCC MMM Humoral 34 M XLA XL BTK:EX2-EX3del / IVIG 2.7 NA
38 CCC MMM Phagocytic 11 M SCN AD ELA2:c.362T>C,p.L121P / G-CSF 3.12 NA
39 CCC MMM Phagocytic 51 M SCN AD ELA2:c.362T>C,p.L121P / / NA NA